<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03429595</url>
  </required_header>
  <id_info>
    <org_study_id>ATx201-004</org_study_id>
    <nct_id>NCT03429595</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With Impetigo</brief_title>
  <official_title>Randomized, Double-Blind, Vehicle Controlled, Phase 2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Activity of Topical ATx201 GEL (2% and 4%) in Outpatients With Impetigo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AntibioTx A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AntibioTx A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2 study evaluating the safety, tolerability, systemic exposure, and activity
      of topical ATx201 GEL (2% and 4%) treatment for 1, 2, or 5 days in outpatients with primary
      nonbullous or bullous impetigo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 23, 2018</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomly assigned (stratified by age) by using an Interactive Web Response System (IWRS) to one of five treatment groups</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidences of Adverse Events and Laboratory Parameters</measure>
    <time_frame>14 days</time_frame>
    <description>incidences of adverse events reports and changes in significant laboratory parameters</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Impetigo</condition>
  <arm_group>
    <arm_group_label>Group 1: ATx201 GEL 2%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: ATx201 GEL 4%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: ATx201 GEL 4% plus vehicle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: ATx201 GEL 4% plus vehicle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5: Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATx201</intervention_name>
    <description>ATx201 GEL</description>
    <arm_group_label>Group 1: ATx201 GEL 2%</arm_group_label>
    <arm_group_label>Group 2: ATx201 GEL 4%</arm_group_label>
    <arm_group_label>Group 3: ATx201 GEL 4% plus vehicle</arm_group_label>
    <arm_group_label>Group 4: ATx201 GEL 4% plus vehicle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ATx201 GEL Vehicle</intervention_name>
    <description>Vehicle</description>
    <arm_group_label>Group 3: ATx201 GEL 4% plus vehicle</arm_group_label>
    <arm_group_label>Group 4: ATx201 GEL 4% plus vehicle</arm_group_label>
    <arm_group_label>Group 5: Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of primary nonbullous or bullous impetigo

          -  affected area comprising 1 to 100 cm2 with surrounding erythema not extending more
             than 2 cm from the edge of any affected area.

          -  target area has total SIRS score of at least 3, including pus/exudate of at least 1

          -  normally active and otherwise in good health by medical history and physical
             examination

        Exclusion Criteria:

          -  has a pre-existing skin condition or skin trauma with clinical evidence of secondary
             infection

          -  has an infection that could not be appropriately treated with a topical antibiotic or
             severe manifestation of impetigo warranting systemic therapy

          -  clinically significant mental illness

          -  pregnant or breast-feeding

          -  recent history, or strong potential for, alcohol or substance abuse.

          -  skin condition that may interfere with the placement of study treatment or impede
             clinical evaluations

          -  receipt of systemic drugs that affect the immune system within the past 3 months

          -  receipt of any topical medication on the regions to be treated or topical antibiotics
             used for nasal decolonization within the past 24 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Months</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Prokocimer, MD</last_name>
    <role>Study Director</role>
    <affiliation>CMO</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wanja Nyoro</last_name>
    <phone>+45 6163 2069</phone>
    <email>Wanja.Nyoro@antibiotx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>AntibioTx Investigational Site</name>
      <address>
        <city>Bloemfontein</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 014</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AntibioTx Investigative Site</name>
      <address>
        <city>Boksburg</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 015</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AntibioTx Investigative Site</name>
      <address>
        <city>Brandfort</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 004</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AntibioTx Investigative Site</name>
      <address>
        <city>Claremont</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 008</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AntibioTx Investigative Site</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 010</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AntibioTx Investigative Site</name>
      <address>
        <city>Germiston</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 016</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AntibioTx Investigative Site 2</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 011</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AntibioTx Investigative Site</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 009</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AntibioTx Investigative Site</name>
      <address>
        <city>Kraaifontein</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 006</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AntibioTx Investigative Site</name>
      <address>
        <city>Mpumalanga</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 001</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AntibioTx Investigative Site</name>
      <address>
        <city>Paarl</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 002</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AntibioTx Investigative Site 2</name>
      <address>
        <city>Port Elizabeth</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 012</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AntibioTx Investigative Site</name>
      <address>
        <city>Port Elizabeth</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 005</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AntibioTx Investigative Site</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 003</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AntibioTx Investigative Site</name>
      <address>
        <city>Soshanguve</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 013</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AntibioTx Investigative Site</name>
      <address>
        <city>Umkomaas</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 007</last_name>
    </contact>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2018</study_first_submitted>
  <study_first_submitted_qc>February 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2018</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Impetigo</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

